Centrexion Therapeutics   Report issue

For profit Phase 1 Phase 3
Founded: Boston MA United States (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2013
NCT00667654
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Centrexion Therapeutics | Centrexion Therapeutics Corp

Active Ingredients

Drugs in Phase 3 Trials (2)

capsaicin (qutenza) (10 trials)

lidocaine (xylocaine) (3 trials)

Drugs in Phase 1 Trials (2)

cntx-6016 (1 trial)

cntx-6970 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chronic Pain (Phase 1)

Herpes Zoster (Phase 1)

Morton Neuroma (Phase 2)

Neuroma (Phase 2)

Nociceptive Pain (Phase 1)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Pain (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 4